

Clerk of the House of Representatives
Legislative Resource Center
3-106 Cannon Building
Washington, DC 20515

Secretary of the Senate
Office of Public Records
232 Hart Building
Washington, DC 20510

SECRETARY OF THE SENATE

00 FEB 10 AM 11:35

H.D.

LOBBYING REPORT

Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page

1. Registrant Name Bristol-Myers Squibb Company			
2. Registrant Address <input type="checkbox"/> Check if different than previously reported Address 655 15th St., NW City Washington, DC State/Zip (or Country) 20005 USA			
3. Principal Place of Business (if different from line 2) City _____ State/Zip (or Country) _____			
4. Contact Name Richard Thompson		Telephone (202) 783-0900	E-mail (optional) _____
5. Senate ID # 7053-E2			6. House ID # 7053
7. Client Name <input checked="" type="checkbox"/> Self			


TYPE OF REPORT 8. Year 1999 Midyear (January 1-June 30) OR Year End (July 1-December 31)

9. Check if this filing amends a previously filed version of this report

10. Check if this is a Termination Report >> Termination Date _____

11. No Lobbying Activity

INCOME OR EXPENSES - Complete Either Line 12 OR Line 13	
12. Lobbying Firms	13. Organizations
INCOME relating to lobbying activities for this reporting period was:	EXPENSES relating to lobbying activities for this reporting period were:
Less than \$10,000 <input type="checkbox"/>	Less than \$10,000 <input type="checkbox"/>
\$10,000 or more <input type="checkbox"/> >> \$ _____ Income (nearest \$20,000)	\$10,000 or more <input checked="" type="checkbox"/> >> \$ <u>\$2,020,000.00</u> Expenses (nearest \$20,000)
14. REPORTING METHOD. Check box to indicate expense accounting method. See instructions for description of options.	
<input checked="" type="checkbox"/> Method A. Reporting amounts using LDA definitions only	
<input type="checkbox"/> Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code	
<input type="checkbox"/> Method C. Reporting amounts under section 162(e) of the Internal Revenue Code	

Signature  Date 2/9/2000

Printed Name and Title Richard Thompson - Vice President, Government Affairs Page 1 of 21

Registrant Name: Bristol-Myers Squibb Company

Client Name: Self

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code BUD (one per page)

16. Specific Lobbying issues
H.R.1906, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2000, Advocate for fair treatment in the WIC program and full funding for the FDA.
S. 1233, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 1999, Advocate for fair treatment in the WIC program and full funding for the FDA.

17. House(s) of Congress and Federal agencies contacted Check if None
Department of Agriculture
House of Representatives
Senate

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)	New
Carozza, Michael		No
Keaney, David		No
Thompson, Richard		No

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

Signature _____ Date 2/9/2000

Printed Name and Title Richard Thompson - Vice President, Government Affairs Page 2 of 21

Registrant Name: Bristol-Myers Squibb Company

Client Name: Self

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code CAW (one per page)

16. Specific Lobbying issues

- EPA: R&D Maximum Achievement Control Technology (MACT), lobbying to discourage EPA from issuing an R&D MACT.
- EPA: Pharmaceutical MACT, lobbying to ensure technical changes to EPA's proposed pharmaceutical MACT rule.
- EPA: Creation of Office of Information to ensure data quality and accessibility.

17. House(s) of Congress and Federal agencies contacted Check if None

Environmental Protection Agency
House of Representatives
Senate

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)	New
<u>Skrabut, Lucy</u>		<u>No</u>

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

Signature _____ Date 2/9/2000

Printed Name and Title Richard Thompson - Vice President, Government Affairs Page 3 of 21

Registrant Name: Bristol-Myers Squibb Company

Client Name: Self

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code CPT (one per page)

16. Specific Lobbying issues

H.R.1225, United States Patent and Trademark Office Reauthorization Act, Fiscal Year 2000, Monitor the effect of the bill on the pharmaceutical industry.

H.R.1598, Patent Fairness Act of 1999, Monitor the effect of the bill on the pharmaceutical industry.

H.R.1907, American Inventors Protection Act of 1999, Monitor the effect of the bill on the pharmaceutical industry.

H.R.769, Madrid Protocol Implementation Act, Monitor the effect of the bill on the pharmaceutical industry.

S.1172, Drug Patent Term Restoration Review Procedure Act of 1999, Monitor the effect of the bill on the pharmaceutical industry.

S.1258, Patent Fee Integrity and Innovation Protection Act of 1999, Monitor the effect of the bill on the pharmaceutical industry.

S.1289, Trademark Amendments Act of 1999, Monitor the effect of the bill on the pharmaceutical industry.

17. House(s) of Congress and Federal agencies contacted

Check if None

Department of Commerce

House of Representatives

Senate

USTR

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)	New
Carozza, Michael		No
Keaney, David		No
Thompson, Richard		No
Warr, David		No

19. Interest of each foreign entity in the specific issues listed on line 16 above

Check if None

Signature _____

Date 2/9/2000

Printed Name and Title Richard Thompson - Vice President, Government Affairs

Page 4 of 21

Registrant Name: Bristol-Myers Squibb Company

Client Name: Self

Item	Description	Data
16	Lobbying Issues	S.671, Madrid Protocol Implementation Act, Monitor the effect of the bill on the pharmaceutical industry.
16	Lobbying Issues	S.804, Technology Transfer Commercialization Act of 1999, Monitor the effect of the bill on the pharmaceutical industry.
16	Lobbying Issues	S.999, Technology Transfer Act of 1999, Monitor the effect of the bill on the pharmaceutical industry.
16	Lobbying Issues	Hatch/Waxman Reform, protecting interests of innovator companies. Protection of Data Exclusivity Agreement, monitoring bills that might impact on Cooperative Research and Development Agreements (CRADA).

Registrant Name: Bristol-Myers Squibb Company

Client Name: Self

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code CSP (one per page)

16. Specific Lobbying issues

H.R.1323, Silicone Breast Implant Research and Information Act, Supporting efforts to limit the ability to admit "junk science" in breast implant liability cases.

S.1075, Silicone Breast Implant Research and Information Act, Supporting efforts to limit the ability to admit "junk science" in breast implant liability cases.

17. House(s) of Congress and Federal agencies contacted Check if None

House of Representatives

Senate

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)	New
Carozza, Michael		No
Keaney, David		No
Ryan, John		No
Thompson, Richard		No

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

Signature _____ Date 2/9/2000

Printed Name and Title Richard Thompson - Vice President, Government Affairs Page 6 of 21

Registrant Name: Bristol-Myers Squibb Company

Client Name: Self

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code ENG (one per page)

16. Specific Lobbying issues
H.R.2050, Electric Consumers' Power To Choose Act of 1999, Supporting electricity deregulation.

17. House(s) of Congress and Federal agencies contacted Check if None
House of Representatives
Senate

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)	New
<u>Skrabat, Lucy</u>		<u>No</u>

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

Signature _____ Date 2/9/2000

Printed Name and Title Richard Thompson - Vice President, Government Affairs Page 7 of 21

Registrant Name: Bristol-Myers Squibb Company

Client Name: Self

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code ENY (one per page)

16. Specific Lobbying issues
H.R.1190, Solid Waste Interstate Transportation and Local Authority Act of 1999, Opposing RCRA reform.

17. House(s) of Congress and Federal agencies contacted Check if None
House of Representatives
Senate

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)	New
<u>Skrabat, Lucy</u>		<u>No</u>

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

Signature _____ Date 2/9/2000

Printed Name and Title Richard Thompson - Vice President, Government Affairs Page 8 of 21

Registrant Name: Bristol-Myers Squibb Company

Client Name: Self

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code FOR (one per page)

16. Specific Lobbying issues

Belgium dioxin contamination. Lobbied to reverse ban on importation of certain products.

Southern Africa AIDS Initiative: Assist South Africa, Botswana, Namibia, Lesotho and Swazilano to find solutions for women and children suffering from the HIV/AIDS epidemic.

Biological Weapons Convention Enforcement Issues: Ensure that an equitable and reasonable compliance protocol is adopted.

New Zealand Pricing Scheme: Lobbied to reverse pricing actions that would effect the reimbursement of certain pharmaceutical products in the country.

17. House(s) of Congress and Federal agencies contacted Check if None

Department of Commerce
Food & Drug Administration
House of Representatives
Senate
U.S. Agency for International Development
U.S. Department of State

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)	New
Carozza, Michael		No
Keaney, David		No
Ryan, John		No
Thompson, Richard		No
Warr, David		No

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

Signature _____ Date 2/9/2000

Printed Name and Title Richard Thompson - Vice President, Government Affairs Page 9 of 21

Registrant Name: Bristol-Myers Squibb Company

Client Name: Self

Item	Description	Data
17a	House of Congress/Agencies	U.S. Trade Representative

Registrant Name: Bristol-Myers Squibb Company

Client Name: Self

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code GOV (one per page)

16. Specific Lobbying issues

H.R.1612, Consumer Food Safety Act of 1999, Monitor bill and advocate position that protect the company's products and the best interests of the consumer.

H.R.1906, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2000, Advocate for fair treatment in WIC program.

H.R.830, Imported Food Safety Act of 1999, Monitor bill and advocate position that protect the company's products and the best interests of the consumer.

S.1123, Imported Food Safety Improvement Act, Monitor bill and advocate position that protect the company's products and the best interests of the consumer.

S.1126, Imported Food Safety Improvement Act of 1999, Monitor bill and advocate position that protect the company's products and the best interests of the consumer.

17. House(s) of Congress and Federal agencies contacted Check if None

**Department of Agriculture
Department of Health and Human Services
House of Representatives
Senate**

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)	New
Carozza, Michael		No
Keaney, David		No
Thompson, Richard		No

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

Signature _____ Date 2/9/2000

Printed Name and Title Richard Thompson - Vice President, Government Affairs Page 11 of 21

Registrant Name: Bristol-Myers Squibb Company

Client Name: Self

Item	Description	Data
16	Lobbying Issues	S.1233. Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2000 . Advocate for fair treatment in WIC program.

Registrant Name: Bristol-Myers Squibb Company

Client Name: Self

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code HCR (one per page)

16. Specific Lobbying issues

H.R.1057, Medical Information Privacy and Security Act, Advocate positions that protect an individual's right to privacy and the industry's need to access data essential for medical research.

H.R.1204, Environmental Equalization and Energy Security Act of 1999, Lobbied for pharmaceutical benefits for Medicare beneficiaries.

H.R.1388, Medicare Cancer Clinical Trial Coverage Act of 1999, Monitor the bill and advocate positions that promote medical research.

H.R.1495, Access to Prescription Medications in Medicare Act of 1999, Lobbied for pharmaceutical benefits for Medicare beneficiaries.

H.R.1596, Consumer Involvement in Breast Cancer Research Act, Monitor the bill and advocate positions that promote medical research.

17. House(s) of Congress and Federal agencies contacted Check if None

Health Care Finance Administration - HCFA

House of Representatives

Senate

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)	New
Carozza, Michael		No
Keuncy, David		No
Thompson, Richard		No

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

Signature _____ Date 2/9/2008

Printed Name and Title Richard Thompson - Vice President, Government Affairs Page 13 of 21

Registrant Name: Bristol-Myers Squibb Company

Client Name: Self

Item	Description	Data
16	Lobbying Issues	H.R.1885, International Prescription Drug Parity Act, Lobbied for pharmaceutical benefits for Medicare beneficiaries.
16	Lobbying Issues	H.R.2457, Genetic Information non discrimination in health insurance., Monitor the effect of the bill on medical research.
16	Lobbying Issues	H.R.2488, Taxpayer Refund and Relief Act of 1999, Lobbied for pharmaceutical benefits for Medicare beneficiaries.
16	Lobbying Issues	H.R.2782, Seniors Prescription Insurance Coverage Equity (SPICE) Act of 1999, Lobbied for pharmaceutical benefits for Medicare beneficiaries.
16	Lobbying Issues	H.R.2925, Medicare Beneficiary Prescription Drug Assistance and Stop-Loss Protection Act of 1999, Lobbied for pharmaceutical benefits for Medicare beneficiaries.
16	Lobbying Issues	H.R.293, Genetic Information Health Insurance Nondiscrimination Act of 1999, Monitor the effect of the bill on medical research.
16	Lobbying Issues	H.R.306, Genetic Information Nondiscrimination in Health Insurance Act of 1999, Monitor the effect of the bill on medical research.
16	Lobbying Issues	H.R.3075, Medicare, Medicaid, and SCHIP Balanced Budget Refinement Act of 1999, Lobby to improve patient access to cancer therapies in hospital outpatient departments.
16	Lobbying Issues	H.R.3426, Medicare, Medicaid, and SCHIP Balanced Budget Refinement Act of 1999, Lobby to improve patient access to cancer therapies in hospital outpatient departments.
16	Lobbying Issues	H.R.547, Taxpayers' Cancer Research Funding Act of 1999, Monitor the bill and advocate positions that promote medical research.
16	Lobbying Issues	H.R.626, Health Care Research and Development and Taxpayer Protection Act, Monitor and advocate positions that will not adversely affect the pharmaceutical industry.
16	Lobbying Issues	H.R.664, Prescription Drug Fairness for Seniors Act of 1999, Lobbied for pharmaceutical benefits for Medicare beneficiaries.
16	Lobbying Issues	H.R.723, Making Affordable Prescriptions Available for Seniors Act, Lobbied for pharmaceutical benefits for Medicare beneficiaries.
16	Lobbying Issues	H.R.785, Biomedical Research Assistance Voluntary Option Act, Monitor the bill and advocate positions that promote medical research.
16	Lobbying Issues	H.R.805, Generic Drugs Access Act of 1999, Monitor and advocate positions that will not adversely affect the pharmaceutical industry.
16	Lobbying Issues	S.1091, Pediatric Research Initiative Act of 1999, Monitor the bill and advocate positions that promote medical research.
16	Lobbying Issues	S.118, Consumer Involvement in Breast Cancer Research Act, Monitor the bill and advocate positions that promote medical research.
16	Lobbying Issues	S.1322, Genetic Information nondiscrimination in health insurance , Monitor the effect of the bill on medical research.
16	Lobbying Issues	S.1462, To amend the Federal Food, Drug, and Cosmetic Act to permit importation in personal baggage and through mail order of certain covered products for personal use from Canada, and for., Lobbied for pharmaceutical benefits for Medicare beneficiaries.
16	Lobbying Issues	S.1480, Seniors Prescription Insurance Coverage Equity (SPICE) Act of 1999, Lobbied for pharmaceutical benefits for Medicare beneficiaries.
16	Lobbying Issues	S.1788, Medicare, Medicaid, and SCHIP Adjustment Act of 1999, Lobby to improve patient access to cancer therapies in hospital outpatient departments.
16	Lobbying Issues	S.1895, Medicare Preservation and Improvement Act of 1999, Lobbied for pharmaceutical benefits for Medicare beneficiaries.
16	Lobbying Issues	S.543, Genetic Information Nondiscrimination in Health Insurance Act of 1999, Monitor the effect of the bill on medical research.
16	Lobbying Issues	S.573, Medical Information Privacy and Security Act, Advocate positions that protect an individual's right to privacy and the industry's need to access data essential for medical research.

Registrant Name: Bristol-Myers Squibb Company

Client Name: Self

Item	Description	Data
16	Lobbying Issues	S.578, Health Care PIN Act, Advocate positions that protect an individual's right to privacy and the industry's need to access data essential for medical research.
16	Lobbying Issues	S.841, Access to Rx Medications in Medicare Act of 1999, Lobbied for pharmaceutical benefits for Medicare beneficiaries.
16	Lobbying Issues	S.881, Medical Information Protection Act of 1999, Advocate positions that protect an individual's right to privacy and the industry's need to access data essential for medical research.
16	Lobbying Issues	House Appropriations 2008 for the Department of Labor, Health and Human Services, and Education, lobby on appropriations level for Ryan White Care Act. Medicare Outpatient Payment Regulations, lobby on regulations governing Medicare reimbursement of hospital outpatients' prescription drugs. Medicare Ostomy Regulations, lobby on coverage and payment for ostomy products.

Registrant Name: Bristol-Myers Squibb Company

Client Name: Self

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code LAW (one per page)

16. Specific Lobbying issues

H.R.1875, Interstate Class Action Jurisdiction Act of 1999, Support the passage of legislation to ensure fair treatment of class action law suits.

H.R.2326, Human Cloning Research Prohibition Act, Monitor the effect of the bill on the legitimate medical research.

H.R.571, Human Cloning Prevention Act of 1999, Monitor the effect of bill on the legitimate medical research.

S.353, Class Action Fairness Act of 1999, Support the passage of legislation to ensure fair treatment of class action law suits.

17. House(s) of Congress and Federal agencies contacted Check if None

House of Representatives

Senate

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)	New
Keaney, David		No
Ryan, John		No

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

Signature _____ Date 2/9/2000

Printed Name and Title Richard Thompson - Vice President, Government Affairs Page 16 of 21

Registrant Name: Bristol-Myers Squibb Company

Client Name: Self

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code MMM (one per page)

16. Specific Lobbying issues

H.R.1544, To require the Secretary of Health and Human Services to establish a demonstration project to provide Medicare beneficiaries greater information with respect to various courses of treatment., Monitor bill and advocate positions that protect the patient and the industry's best interests.

H.R.3075, Medicare, Medicaid, and SCHIP Balanced Budget Refinement Act of 1999, Lobby to improve patient access to cancer therapies in hospital outpatient departments.

H.R.3426, Medicare, Medicaid, and SCHIP Balanced Budget Refinement Act of 1999, Lobby to improve patient access to cancer therapies in hospital outpatient departments.

H.R.358, Patients' Bill of Rights Act of 1999, Monitor bill and advocate positions that protect the patient and the industry's best interests.

17. House(s) of Congress and Federal agencies contacted Check if None

Health Care Finance Administration - HCFA

House of Representatives

Senate

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)	New
Carazza, Michael		No
Keaney, David		No
Thompson, Richard		No

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

Signature _____ Date 2/9/2000

Printed Name and Title Richard Thompson - Vice President, Government Affairs Page 17 of 21

Registrant Name: Bristol-Myers Squibb Company

Client Name: Self

Item	Description	Date
16	Lobbying Issues	H.R.448, Patient Protection Act of 1999, Monitor bill and advocate positions that protect the patient and the industry's best interests.
16	Lobbying Issues	S.1788, Medicare, Medicaid, and SCHIP Adjustment Act of 1999, Lobby to improve patient access to cancer therapies in hospital outpatient departments.
16	Lobbying Issues	S.240, Patients' Bill of Rights Act of 1999, Monitor bill and advocate positions that protect the patient and the industry's best interests.
16	Lobbying Issues	S.300, Patients' Bill of Rights Plus Act, Monitor bill and advocate positions that protect the patient and the industry's best interests.
16	Lobbying Issues	S.326, Patients' Bill of Rights Act, Monitor bill and advocate positions that protect the patient and the industry's best interests.
16	Lobbying Issues	S.374, Promoting Responsible Managed Care Act of 1999, Monitor bill and advocate positions that protect the patient and the industry's best interests.
16	Lobbying Issues	S.6, Patients' Bill of Rights Act of 1999, Monitor bill and advocate positions that protect the patient and the industry's best interests.
16	Lobbying Issues	S.751, Seniors Safety Act of 1999, Monitor bill and advocate positions that protect the patient and the industry's best interests.
16	Lobbying Issues	Medicare Outpatient Payment Regulations, lobbying on regulations governing Medicare reimbursement of hospital outpatient prescription drugs. Medicare Ostomy Regulations, lobby on coverage and payment for ostomy products.

Registrant Name: Bristol-Myers Squibb Company

Client Name: Self

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code TAX (one per page)

16. Specific Lobbying issues

R&D Tax Credit, to make permanent the research and development tax credit.

China/Puerto Rico Tariff Issue: China has levied much higher Chinese customs duties on Puerto Rico manufactured products.

17. House(s) of Congress and Federal agencies contacted Check if None

House of Representatives

Senate

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)	New
Carozza, Michael		No
Kenney, David		No
Ryan, John		No
Thompson, Richard		No
Warr, David		No

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

Signature _____ Date 2/9/2000

Printed Name and Title Richard Thompson - Vice President, Government Affairs Page 19 of 21

Registrant Name: Bristol-Myers Squibb Company

Client Name: Self

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code TRD (one per page)

16. Specific Lobbying issues

H.R.434, African Growth and Opportunity Act, Establishes a U.S. policy of trade and investment with the emerging economies of sub-Saharan Africa.

S.666, African Growth and Opportunity Act, Establishes a U.S. policy of trade and investment with the emerging economies of sub-Saharan Africa.

17. House(s) of Congress and Federal agencies contacted Check if None

House of Representatives
Senate
The Department of Health and Human Services
The Food and Drug Administration

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)	New
Keaney, David		No
Thompson, Richard		No
Warr, David		No

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

Signature  Date 2/9/2000

Printed Name and Title Richard Thompson - Vice President, Government Affairs Page 20 of 21

Registrant Name: Bristol-Myers Squibb Company

Client Name: Self

Item	Description	Data
16	Lobbying Issues	Canada Patent Issue: Canada's failure to provide 20 year patent term in accordance with GATT/TRIPS. China/Puerto Rico Tariff Issue: China has levied much higher Chinese customs duties on Puerto Rico manufactured products. Data Exclusivity: South Africa, The Netherlands, Canada, lobby Congress, Department of State and U.S. Trade Representative to enforce data exclusivity provisions under GATT TRIPs provision.